The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Subgroup analyses of the TRANSCEND-NHL-001 MCL cohort: the effect of prior LOT & BTKi refractoriness
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, presents the findings of post-hoc subgroup analyses of data from the relapsed/refractory (R/R) mantle cell lymphoma (MCL) cohort treated with lisocabtagene maraleucel (liso-cel) as part of the TRANSCEND-NHL-001 study (NCT02631044). These analyses focused on patient responses to liso-cel based on prior lines of therapy (LOT) and refractoriness to prior BTK inhibitor (BTKi) treatment. Dr Kamdar highlights that patient responses to liso-cel were comparable to the overall population. However, patients with 5 or more prior lines of therapy and those refractory to BTKi treatment demonstrated poorer responses, with the complete response (CR) rate in this subgroup of patients being over 10% lower. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
